OTTAWA, Jan. 8, 2014 /CNW/ - Annidis Corporation (TSX Venture: RHA) ("Annidis" or the "Corporation") is pleased to announce that further to its news release of December 10, 2013, the TSX Venture Exchange ("TSXV") has approved its application to extend the expiry date of 3,531,250 issued and outstanding common share purchase warrants (the "Warrants") in accordance with TSXV Policy 4.1.
The Warrants were originally issued by Annidis Health Systems Corp. - the Corporation's QT Target Company - prior to the completion of the Corporation's QT, and were subsequently exchanged for Annidis share purchase warrants upon completion of the Corporation's QT which was accepted by the TSXV on June 10, 2011. The Warrants are exercisable at prices of $0.30 and $0.40 per common share and were set to expire between December 18, 2013, and November 4, 2014. Further to the Corporation`s extension application, the TSXV has agreed, in accordance with TSXV Policy 4.1, to permit the term of the Warrants to be extended from 4 years to 5 years as follows:
| Number of
|250,000||$ 0.40||18-Dec-09||4 Years||18-Dec-13||5 Years||18-Dec-14|
|125,000||$ 0.40||22-Dec-09||4 Years||22-Dec-13||5 Years||22-Dec-14|
|500,000||$ 0.30||15-Mar-10||4 Years||15-Mar-14||5 Years||15-Mar-15|
|581,250||$ 0.30||14-May-10||4 Years||14-May-14||5 Years||14-May-15|
|168,750||$ 0.30||28-May-10||4 Years||28-May-14||5 Years||28-May-15|
|625,000||$ 0.30||30-Jun-10||4 Years||30-Jun-14||5 Years||30-Jun-15|
|343,750||$ 0.30||30-Jul-10||4 Years||30-Jul-14||5 Years||30-Jul-15|
|125,000||$ 0.30||03-Aug-10||4 Years||03-Aug-14||5 Years||03-Aug-15|
|125,000||$ 0.30||16-Aug-10||4 Years||16-Aug-14||5 Years||16-Aug-15|
|31,250||$ 0.30||24-Aug-10||4 Years||24-Aug-14||5 Years||24-Aug-15|
|125,000||$ 0.30||29-Sep-10||4 Years||29-Sep-14||5 Years||29-Sep-15|
|125,000||$ 0.30||13-Oct-10||4 Years||13-Oct-14||5 Years||13-Oct-15|
|31,250||$ 0.30||19-Oct-10||4 Years||19-Oct-14||5 Years||19-Oct-15|
|125,000||$ 0.30||27-Oct-10||4 Years||27-Oct-14||5 Years||27-Oct-15|
|250,000||$ 0.30||04-Nov-10||4 Years||04-Nov-14||5 Years||04-Nov-15|
The exercise price of the Warrants will remain unchanged.
About Annidis Corporation
Annidis (TSX-V: RHA) has developed and is marketing a new imaging platform technology based on Multi-Spectral Imaging (MSI). This new technology is opening a new frontier in disease identification and its management. The Annidis MSI technology allows eye-care professionals to view non-invasively the deepest areas of the eye aiding eye care professionals in the early identification and treatment of debilitating eye diseases. The Company's existing RHA 2020-U Gold, used by eye care professionals as a broad based tool for detecting early-onset of eye related diseases such as Dry AMD, has a potential market of over 20,000 clinics in North America. The RHA Platinum MD will further strengthen the value proposition allowing doctors to visualize choroidal and retinal vasculature non-invasively. The RHA Platinum MD has global market potential of more than 100,000 Ophthalmologists
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
SOURCE: Annidis Corporation
For further information:
Chief Executive Officer
(519) 858-1582 ext. 239
Virtus Advisory Group Inc.